Compositions and methods for reducing at least one symptom of human allergy to cats

11649,278

16/988829

August 10, 2020

Compositions and methods reduce symptoms of human allergy to cats. The effectiveness of a molecule which specifically binds to Feline domesticus allergen number 1 (Fel D1) is enhanced by prolonging the time the immunoglobulin stays within the mouth of a cat to whom the anti-Fel D1 molecule is administered in a pet food. The compositions and methods use a powder that is a dried hydrogel encapsulating the anti-Fel D1 molecule, and the hydrogel is based on gelatin, collagen peptides, or gelatin and collagen peptides; and carrageenan. The methods of making the powder provide a high encapsulation efficacy, sustained release of the anti-Fel D1 molecule in the cat's mouth, and oral adhesion of the anti-Fel D1 molecule in the cat's mouth.

Société des Produits Nestlé S.A. (Vevey, CH)

SOCIÉTÉ DES PRODUITS NESTLÉ S.A. (Vevey, CH)

1. A method of making a food grade powder providing sustained release of an anti-Fel D1 molecule, the method comprising: heating a solution comprising gelatin, carrageenan and the anti-Fel D1 molecule; forming droplets of the heated solution; gelling the droplets by subjecting the droplets to a gelling bath comprising salt or oil to form gelled beads in which the anti-Fel D1 molecule is encapsulated; and drying the gelled beads to form the food grade powder.

2. The method of claim 1 , wherein the gelling bath comprises about 100 mM of potassium chloride, about 100 mM calcium chloride, or both.

3. The method of claim 1 , wherein the drying comprises subjecting the beads to fluid bed drying.

4. The method of claim 1 , wherein the gelatin and the carrageenan are the only biopolymers capable of gelling below 60° C. in the dried hydrogel.

5. A method of making a food grade powder providing sustained release of an anti-Fel D1 molecule, the method comprising: heating a solution comprising gelatin, carrageenan, and the anti-Fel D1 molecule; extruding the heated solution to cool and shape the heated solution and form an extruded hydrogel in which the anti-Fel D1 molecule is encapsulated; and drying the extruded hydrogel.

6. The method of claim 5 , wherein the extruding is performed by a tubular heat exchanger having a temperature of about 0.1° C. to about 35° C.

7. The method of claim 5 , further comprising immersing the extruded hydrogel in a composition comprising calcium, magnesium potassium, rubidium, or cesium before the drying.

8. The method of claim 5 , wherein the drying comprises subjecting the extruded hydrogel to a drying tunnel, oven, or fluid bed drier.

9. A method of reducing symptoms of human allergy to a cat, the method comprising orally administering to the cat an effective amount of a food grade powder, wherein the food grade powder provides sustained release of an anti-Fel D1 molecule, wherein the food grade powder comprises a dried hydrogel and the anti-Fel D1 molecule, and wherein the dried hydrogel is a co-gel comprising carrageenan and a member selected from the group consisting of gelatin, collagen peptides, and gelatin and collagen peptides; wherein the anti-Fel D1 molecule is encapsulated in the dried hydrogel.

10. The method of claim 9 , wherein the composition is administered as part of a pet food further comprising at least one component selected from the group consisting of protein, fat, carbohydrate, vitamin and mineral.

11. The method of claim 9 , wherein the gelatin or the gelatin and collagen peptides are from Type A porcine gelatin having a positive charge at a pH below 7.0.

12. The method of claim 9 , wherein the carrageenan is selected from the group consisting of (i) kappa-carrageenan, (ii) iota-carrageenan, (iii) a physical mixture of kappa-carrageenan and iota-carrageenan and (iv) a co-polymer of kappa-carrageenan and iota-carrageenan.

13. The method of claim 9 , wherein the gelatin and the carrageenan are the only biopolymers in the dried hydrogel.

14. The method of claim 9 , wherein the dried hydrogel is a spray-dried hydrogel comprising the anti-Fel D1 molecule and 0.5 to 90 wt. % of gelatin, and the powder has a density of about 0.265 to about 0.3 g/cm 3 .

15. The method of claim 14 , wherein the gelatin and collagen peptides have a molecular weight between 2,000 and 1 million Daltons and a bloom value of 40 to 300.

16. The method of claim 14 , comprising 25.0 to 60.0 wt. % of the gelatin and 40 to 75 wt. % of a source of the anti-Fel D1 molecule.

8877705 November 2014 Larreta-Garde et al.
10774137 September 2020 Wooster
20130236475 September 2013 Wells et al.
20130296165 November 2013 Harel et al.
103251971 August 2013
104147627 November 2014
62289530 December 1987
2491937 September 2013
9403159 February 1994
2002072636 September 2002
2008103046 August 2008
2009009061 January 2009
2011048388 April 2011
2013166236 November 2013

Shewan et al., “Review of Techniques to Manufacture Micro-Hydrogel Particles for the Food Industry and their Applications”, Journal of Food Engineering, vol. 119, Issue No. 4, 2013, pp. 781-792. cited by applicant
Yegappan et al., Carrageenan based hydrogeis for drug delivery, tissue engineering and wound healing, Carbohydrate Polymers vol. 198, Oct. 15, 2018, pp. 385-400. cited by applicant
Muller et al., “IgY antibodies in human nutrition for disease prevention”, Nutrition Journal, BioMed Central, vol. 14, Oct. 20, 2015, pp. 1-7, XP021230354. cited by applicant
International Search Report & Written Opinion to PCT/IB2018/050320 dated Apr. 17, 2018. cited by applicant
Australian Microbiological Limits for Food, Issue 53 and 70, Standard 1.6.1. cited by applicant
Moritaka, et al., “Rheological Properties of Aqueous Agarose-Gelatin Gels”, Journal of Texture Studies 11 (1980) 257-270 Japan. cited by applicant
Fujii et al. “Mechanical Properties of Two-Phase Disperse Agar/Gelatin Mixed Gels”, Journal of Texture Studies 31 (2000) 273-286 Japan. cited by applicant
Bonferoni et al., Carrageenan-gelatin mucoadhesive systems for ion-exchange based opthalmic delivery: in vitro and preliminary in vivo studies European Journal of Pharmaceutics and Biopharmaceutics 57 (2004) 465-472 Italy. cited by applicant
Fang et al., “Associative and Segregative Phase Separations of Gelalin/k-Carrageenan Aqueous Mixtures”, Langmuir 2006 22, 9532-9537 The Netherlands. cited by applicant
Jonganurakkun, et al., “Survival of lactic acid bacteria in simulated gastrointestinal juice protected by a DNA-based complex gel” J Biomater Sci Polymer Edn (2003) vol. 14 No. 11, pp. 1269-1281. cited by applicant
Coste, et al., “Study of the Poly-Lysine Release from Polysaccharides/Gelatin Hydorgels”, Proceed. Int'l. Symp. Control. Rel. bioact. Mater, 27(2000) Controlled Release Society, pp. 744-745 France. cited by applicant
Lam, el al., “Development of formaldehyde-free agar/gelatin microcapsules containing berberine HCI and gallic acid and their topical and oral applications”, Soft Matter 2012, 8 5027-5037. cited by applicant
Girod, et al. “Characerization of a gelatin/polysaccharides mixed hydrogel,” Proceeds Int'l. Symp. Control. Rel. Boact Mater 2000 27th 760-761. cited by applicant
Devi, et al., Genipin crosslinked microcapsules of gelatin A and k-carrageenan polyelectrolyte complex for encapsulation of Neem (Azadiracta Indica A.Juss) seed oil Polym.Bull. 2010 65 374-362. cited by applicant
Varghese, et al. “Gelatin-carrageenan hydrogels: Role of pore size distribution on drug delivery process” Colloids and Surfaces B. Biointerfaces 2014 113, 346-351 India. cited by applicant
Saxena, et al. “Rheological properties of binary and ternary protein-polysaccharide co-hydrogels and comparative release kinetics of salbutamol sulphate from their matrices” International Journal of Biological Macromolecules 2011 48, 263-270 India. cited by applicant
Devi et al., Microencapsulation of isoniazid in genipin-crosslinked gelatin-A-k-carrageenan polyelectrolyte complex Drug Development and Industrial Pharmacy 2010 36(1) 56-63 India. cited by applicant
Lundin, et al., “Phase Separation in Mixed Carrageenan Systems”, Proceedings to Supermolecular and Colloidal Structures in Biomaterials and Biosubstrates 1999 (Supplied by the British Library) pp. 436-449. cited by applicant
https://www.youtub.com/watch?v=6bYlow9pc6M Published on Feb. 21, 2011 Connect with GELITA: Visit our WEBSITE: https://www.gelita.com/. cited by applicant
Nguyen et al., “Advanced Drug Delivery Systems for Local Treatment of the Oral Cavity”, Therapeutic Delivery, vol. 6, Issue No. 5, 2015, pp. 595-608. cited by applicant
Varghese et al., “Gelatin-Carrageenan Hydrogels: Role of Pore Size Distribution on Drug Delivery Process”, Colloids and Surfaces B: Biointerfaces, vol. 113, 2014, pp. 346-351. cited by applicant

edspgr.11649278